iLoF is a digital health company building an AI and photonics platform for personalized drug discovery and development. The system creates a cloud-based library of optical fingerprints for disease biomarkers, allowing pharmaceutical and clinical teams to stratify patients with greater precision across areas including neurodegenerative disease, infectious disease, oncology and cardiovascular indications.
The core product is a proprietary photonics and AI-powered platform that analyses blood samples using only light and machine learning. It requires just microlitres of blood, completes analysis in under 10 seconds and uses no consumables. Reported outcomes include a 70% reduction in time spent on clinical trial screenings and 40% cost savings.
Engineering work spans artificial intelligence, photonics, optical fingerprinting, biomarker detection and cloud-based data infrastructure. Teams are distributed across Oxford, London and Porto, with additional international locations, and the company has Oxford-affiliated roots.
iLoF has been recognised by CB Insights and the Financial Times among promising digital health companies globally, and is backed by investors including Microsoft Ventures (M12), Mayfield, Pivotal Ventures and EIT Health. Its stated aim is to widen access to personalised medicine.
